SCHEMBL3244243

SCHEMBL3244243

COc1ccc(Br)cc1C(=O)NC(c1ccccc1)C(C)(C)N1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
DRD3 P35462 4/20 0.47
POLB P06746 3/20 0.46
LMNA P02545 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 2/20 0.45
DRD2 P14416 4/20 0.44
DRD4 P21917 3/20 0.44
SIGMAR1 Q99720 1/20 0.44
STAT3 P40763 1/20 0.43
MAPT P10636 1/20 0.42
GFER P55789 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8265566 0.88 ALDH1A1 (0.42) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL3235882 0.84 ALDH1A1 (0.40) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL3238330 0.84 KDM4E (0.49) POLBLMNANPSR1ALDH1A1KDM4E
SCHEMBL3238315 0.83 ALDH1A1 (0.41) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL3235817 0.82 TAS1R3 (0.41) ALDH1A1KDM4EMAPTHPGDRXFP1
SCHEMBL3241301 0.82 MEN1 (0.42) MEN1KMT2ALMNANPSR1ALDH1A1
SCHEMBL3239516 0.81 ALDH1A1 (0.41) DRD3ALDH1A1KDM4EDRD2DRD4
SCHEMBL3239749 0.81 DRD3 (0.44) MEN1KMT2ADRD3ALDH1A1DRD2
SCHEMBL3239591 0.81 KMT2A (0.47) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL8265337 0.81 ALDH1A1 (0.40) MEN1KMT2AALDH1A1KDM4EDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 MEN1 2501/4885KMT2A 1871/4885DRD3 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.